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OBJECTIVES We examined whether oral folate supplementation would rescue a hypercholesterolemia
(HC)-related impairment of ischemia-induced angiogenesis.
BACKGROUND Folate protects against endothelial dysfunction, but the effect of folate supplementation on
angiogenesis is little known.
METHODS Sprague-Dawley rats were divided into four groups. Control rats were fed a normal diet (n 
18); HC rats (n  18) were fed 2% cholesterol diet; and HC  folate (HCF) rats were fed
an HC diet with oral folate (0.003% in water). The left femoral artery and vein were surgically
excised, and angiogenesis in the ischemic limb was evaluated. We also examined the effects
of N-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) synthase,
on angiogenesis in the HCF state.
RESULTS Laser Doppler blood flow (LDBF) analysis showed lower ischemic/normal LDBF ratio in the
HC group than in the control group. Angiographic and histologic analyses on day 14 revealed
a smaller angiographic score (p  0.001) and capillary density (p  0.001) in the HC group
than in controls, which were associated with reduced tissue NOx and cyclic guanosine
monophosphate (cGMP) levels. The LDBF ratio, angiographic score, and capillary density
were significantly restored in the HCF group (p  0.01 vs. HC), which were associated
with increased serum folate and tissue NOx and cGMP levels. Finally, L-NAME treatment
abolished the beneficial action of folate on angiogenesis in the HC state.
CONCLUSIONS Ischemia-induced angiogenesis was inhibited by HC, which was rescued by oral folate
supplementation, at least in part, via an NO-dependent manner. (J Am Coll Cardiol 2003;
42:364–72) © 2003 by the American College of Cardiology Foundation
Enhancement of collateral vessel formation and angiogen-
esis in patients with peripheral artery occlusive disease is an
important strategy for minimizing ischemia-induced tissue
injury, termed “therapeutic angiogenesis” (1). Neovascular-
ization is stimulated by various cytokines to grow into
ischemic foci, in which migration and proliferation of
endothelial cells are essential events. We and other investi-
gators (2,3) reported that endothelium-derived nitric oxide
(EDNO) is an important regulator for angiogenesis. For
example, angiogenesis induced by vascular endothelial
growth factor was attenuated by inhibitors of nitric oxide
synthase (NOS) (2). We also showed that ischemia-induced
angiogenesis was reduced in mice lacking the gene for
endothelial nitric oxide synthase (eNOS) (3).
Hypercholesterolemia (HC) is an established risk factor
for atherothrombotic disease and is associated with endo-
thelial dysfunction as characterized by impaired
endothelium-dependent vasorelaxation (i.e., EDNO re-
lease) (4). The adverse effects of HC on vascular function
were recently extended into the process of angiogenesis
(5,6). For example, HC impairs ischemia-induced angio-
genesis (5), which is mediated by a reduced endogenous
EDNO formation (6).
Studies showed that folate and its active metabolite
5-methyltetrahydrofolate caused a reversion of HC-induced
endothelial dysfunction through enhancement of nitric ox-
ide (NO) production by regenerating tetrahydrobiopterin
(BH4), a cofactor for NOS (7–11). Despite these beneficial
actions of folate on the endothelium, the effects of oral
folate supplementation on angiogenesis are little known.
Accordingly, the present study was designed to test whether
oral supplementation of folate would rescue the HC-related
impairment of angiogenesis in a rat model of hindlimb
ischemia.
METHODS
Experimental protocol. We employed a rat model of
unilateral hindlimb ischemia as described previously (6,12).
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of Kurume Uni-
versity School of Medicine. Male Sprague-Dawley rats (n
54) were randomly divided into three groups. Control (n 
18) rats were fed a normal diet and tap water; HC rats (n
18) were fed a 2% cholesterol diet and tap water; hyper-
cholesterolemia plus folate (HCF) rats (n  18) were fed
the HC diet and drinking water containing folate (0.003
vol%). Two weeks later, all rats were subjected to unilateral
hindlimb ischemia by removing the left femoral artery and
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vein (6,12). From the day of surgery until the end of the
protocol, the HCF rats continued to receive folate. The
oral dose of folate was chosen according to a previous study
(13), and this regimen (5 mg/kg/day) effectively increased
serum levels of folate. Before and at days 7, 14, and 28,
systemic blood pressure and heart rate were measured in the
conscious state using a tail-cuff method (TK-370C, UNI-
COM, Tokyo, Japan).
Laser Doppler blood flow analysis. We measured the
ratio of ischemic (left)/normal (right) hindlimb blood flow
using a laser Doppler blood flow (LDBF) analyzer
(moorLDI, Moor Instrument, Wilmington, Delaware) as
described previously (6,12,14). At six time points (before
and at days 1, 7, 14, 21, and 28), we performed laser
Doppler scanning over the regions of interest (legs and feet).
The average perfusion of the ischemic (left) and nonisch-
emic (right) hindlimbs was computed, and blood flow was
expressed as the ischemic (left)/normal (right) hindlimb
blood flow ratio.
Angiographic score. At day 14, under pentobarbital anes-
thesia, a 26-gauge catheter was inserted into the abdominal
aorta of control (n  6), HC (n  6), and HCF (n  6)
rats. Hindlimbs were perfused with 10 mL of warm saline
containing heparin (10 U/ml) at 90 mm Hg of perfusion
pressure. After animals were euthanized by a high dose of
pentobarbital, postmortem hindlimb angiography was per-
formed as described previously (6). The medial thigh
adductor muscle area of the ischemic limb was selected to
quantify the developed collateral vessels (i.e., angiographic
score). Angiographic scores were calculated as described
previously (6).
Capillary density. An additional six animals in each group
were euthanized at day 14, and ischemic (left) and nonisch-
emic (right) hindlimb skeletal muscles (quadriceps muscles)
were harvested and fixed in methanol. Tissues were embed-
ded in paraffin, and 5-m-thick sections were prepared. We
used a monoclonal antibody directed against von Wille-
brand Factor (F8/86, DAKO, Glostrup, Denmark) as a
marker of endothelium. Capillary endothelial cells positively
stained with this monoclonal antibody were counted using
light microscopy, and the capillary densities of both isch-
emic and nonischemic hindlimb skeletal muscles were
calculated and expressed as the number of capillaries/high
power field (400) (12). To ensure that analysis of capillary
density was not overestimated as a result of muscle atrophy
or underestimated because of interstitial edema, the capil-
lary/muscle fiber ratio was also determined.
Tissue contents of cyclic guanosine monophosphate
(cGMP) and nitrate  nitrate (NOx). The medial thigh
adductor muscles were harvested from the ischemic hind-
limb of six rats in each group at day 14. The tissue samples
were weighed, snap-frozen in liquid N2 and stored at
80°C. The assay for cyclic guanylate monophosphate
(cGMP) was performed as described previously (3). Tissue
NOx content was measured by a high-performance liquid
chromatography as described (6).
Additional biochemical analysis. Plasma and tissue levels
of NOx were measured by high-performance liquid chro-
matography (15). Plasma levels of homocysteine, folate, and
vitamin B12 were also measured by high-performance liquid
chromatography as described elsewhere (16–18). Serum
concentrations of total- and high-density lipoprotein cho-
lesterol were determined enzymatically using commercially
available kits (Boehringer Diagnostica, Mannheim, Ger-
many, and Wako Chemicals, Richmond, Virginia).
Effects of NO inhibition on the folate-mediated modifi-
cation of angiogenesis. To examine whether the effects of
folate on angiogenesis is related to in vivo NO bioactivity,
we tested the effects of oral administration of NOS inhib-
itor, N-nitro-L-arginine methyl ester (L-NAME), on
folate-mediated modification of angiogenesis. In an addi-
tional group of rats (n  12), HCF diet was started at 14
days before limb ischemia surgery. On the day of surgery,
oral L-NAME administration (1.0 mg/ml in drinking
water) was started, and LDBF and angiographic score were
analyzed thereafter. The dose of L-NAME was determined
according to a previous study (19), and this regimen
effectively inhibited endogenous NOS bioactivity (19).
Reagents. All reagents were purchased from Sigma unless
otherwise specified. The immunostaining kit (VEC-
TASTAIN) including the secondary anti-mouse IgG poly-
clonal antibody was purchased from Vector Laboratories.
Statistical analysis. Results are all expressed as means 
SE. Comparisons were performed by one-way analysis of
variance, which were followed by the Fisher least significant
difference test for comparisons between any two groups.
Statistical significance was assumed at p  0.05.
RESULTS
Table 1 summarizes the mean body weight, heart rate, and
systolic arterial blood pressure of the four experimental
groups measured before surgery and at postoperative days 7,
14, and 28. Body weight was higher in the HC and HCF
groups than in the control group at days 7, 14, and 28.
There were no significant differences in body weight be-
tween the HC and HCF groups at any time point,
indicating that supplemental oral folate did not affect body
weight. There were no significant differences in heart rate
Abbreviations and Acronyms
BH4  tetrahydrobiopterin
cGMP  cyclic guanosine monophosphate
eNOS  endothelial nitric oxide synthase
EDNO  endothelium-derived nitric oxide
HC  hypercholesterolemia
HCF  hypercholesterolemia plus folate
LDBF  laser Doppler blood flow
L-NAME  N-nitro-L-arginine methyl ester
NO  nitric oxide
NOS  nitric oxide synthase
NOx  nitrate  nitrite
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nor in systolic blood pressure among the groups at any time
points examined (Table 1).
Serum cholesterol and plasma folate levels. Table 2
summarizes serum cholesterol and plasma folate levels at
postoperative day 14. The plasma folate level significantly
increased in the HCF group compared with the control
and HC groups. Serum total-cholesterol modestly but
significantly increased in the HC and HCF groups
compared with the control group. Serum high-density
lipoprotein cholesterol significantly decreased in the HC
and HCF groups compared with the control group. There
were no significant differences in total or high-density
lipoprotein cholesterol levels between the HC and HCF
groups, indicating that oral folate supplementation did not
affect serum cholesterol levels under the HC condition.
Laser Doppler analysis for hindlimb blood flow. Figure
1A shows representative images of the hindlimb blood flow
as assessed by laser Doppler at postoperative days 7, 14, and
28. Serial LDBF analyses revealed a progressive recovery of
the blood flow within 28 days after induction of hindlimb
ischemia in the control group. The recovery of blood flow in
the ischemic hindlimb was significantly impaired in the HC
group. However, oral folate supplementation (HCF
group) contributed to the recovery of blood flow in the
ischemic hindlimb. Before surgery, the ratio of the ischemic
(left)/normal (right) hindlimb LDBF was approximately 1.0
in all three groups (Fig. 1B), indicating no differences in
blood flow between right and left legs. Immediately after
surgical induction of left limb ischemia, the ischemic/
normal LDBF ratio markedly decreased to almost 0.4 in all
three groups. These values did not differ among the groups,
indicating that the severity of the induced limb ischemia was
comparable among the groups.
During the follow-up period, the ischemic/normal LDBF
ratio was significantly lower in the HC group than in the
control group at postoperative days 7, 14, 21, and 28.
However, the recovery of the ratios was much greater in the
HCF group than in the HC group at these time points
(Fig. 1B).
Iliac arteriography and determination of the angio-
graphic score. To examine whether the reduced LDBF
ratio in the HC group was associated with a decrease in the
angiographically visible collateral vessel formation (arterio-
genesis), we performed postmortem angiography at postop-
erative day 14. There were many collateral vessels issuing
from the internal iliac artery in the ischemic medial thigh in
the control group. In contrast, the HC group had fewer
collateral vessels in this area. The HCF group, however,
revealed an enhanced formation of collateral vessels com-
pared with the HC group (Fig. 2A). The mean angio-
graphic score on postoperative day 14 was significantly
lower in the HC group than in the control group, whereas
it was restored in the HCF group almost to the level of
the control group (Fig. 2B).
Tissue capillary density. Using an anti- von Willebrand
factor monoclonal antibody, we performed immunohisto-Ta
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chemical staining for the capillary endothelial cells in both
ischemic and nonischemic hindlimb tissues at postoperative
day 14. Quantitative analysis in the ischemic hindlimb
tissues revealed a significant decrease in the capillary density
in the HC group compared with the control group. How-
ever, the capillary density was significantly increased in the
HCF compared with the HC group. Similarly, the
capillary/muscle fiber ratio, which can exclude the effects of
interstitial edema or muscular atrophy on capillary counts,
was decreased in the HC group and was restored in the
HCF group. In the nonischemic hindlimb tissues, the
capillary density, and capillary/muscle fiber ratio did not
differ among the three groups (Fig. 3).
Plasma levels of NOx and tissue contents of NOx and
cGMP. The plasma NOx level significantly decreased in
the HC group compared with the control group, whereas it
was restored in the HCF group (Table 2). Serum vitamin
B12 level did not differ among the three groups (data not
shown). We further analyzed the tissue contents of cGMP
and NOx in the ischemic hindlimb (n  6 in each group).
Tissue NOx and cGMP contents significantly decreased in
the HC group as compared with the control group, while
they were restored in the HCF group (Table 2).
Plasma level of homocysteine. The plasma level of
homocysteine significantly increased in the HC group
compared with the control group (p  0.001), while it was
restored in the HCF group to a level similar to that of the
control group (p  0.001 vs. HC) (n  6 in each group)
(Table 2).
Effects of NO inhibition on folate-modification of an-
giogenesis in the HC state. Because ischemia-induced
angiogenesis depends on EDNO formation, we examined
the effects of L-NAME on angiogenesis in the HCF
group. Figure 4A shows the time course of the ischemic/
normal hindlimb LDBF ratio. Folate treatment restored the
LDBF ratio in the HC state. However, co-administration
of L-NAME significantly suppressed the LDBF ratio to a
level much lower than that in the HC group. Figure 4B
shows the angiographic score examined on postoperative
day 14. Again, folate treatment restored the angiographic
score of the HC state. However, co-administration of
L-NAME markedly suppressed the score, which was lower
than that in the HC group.
DISCUSSION
The present study demonstrated that ischemia-induced
angiogenesis was impaired by HC, a major risk factor for
atherosclerosis, in a rat model of hindlimb ischemia. The
impaired angiogenesis in HC rats was associated with
reduced plasma NOx, tissue NOx, and cGMP levels,
indicating reduced endogenous NO bioactivity. Impor-
tantly, the present study for the first time demonstrated that
the HC-related impairment of angiogenesis was restored by
oral supplementation of folate. The rescue effect was, at least
in part, related to increased NO bioactivity because
L-NAME completely suppressed the effects of folate on
angiogenesis.
Mechanisms for the HC-related impairment of angio-
genesis. There are several possible mechanisms for the
HC-related impairment of angiogenesis. First, HC-
mediated endothelial dysfunction may account for the major
part of the impaired angiogenesis. It has been shown that
HC impairs endothelial function, including EDNO forma-
tion (4), and EDNO is a critical regulator for angiogenesis
(2,3). For example, we showed that ischemia-induced an-
giogenesis was markedly attenuated in mice lacking the
eNOS gene (3). Endothelium-derived NO also supports
endothelial migration (20). Therefore, impaired EDNO
formation in dysfunctional endothelium during HC may, at
least in part, account for the impaired angiogenesis. Indeed,
both plasma and tissue levels of NOx and cGMP, a second
messenger of NO, were significantly decreased in the HC
group compared with controls in the present study, indicat-
ing a reduced NO bioavailability in HC.
Second, eNOS has been shown to produce not only NO
but also superoxide radical (21). Under physiologic condi-
tions, eNOS produces NO. However, it produces superox-
ide anion under dyslipidemic conditions, resulting in an
increase of endothelial oxidative stress in the HC state
(22,23). Moreover, HC itself may have directly inhibited
the migration and/or proliferation of endothelial cells. A
recent study demonstrated that oxidized low-density li-
poprotein inhibited endothelial migration (24). Chen et al.
(25,26) also showed that ex vivo angiogenesis from explants
of human and rabbit coronary artery segments was signifi-
cantly impaired in HC compared with healthy subjects.
Likewise, superoxide anion directly deteriorates endothelial
Table 2. Plasma and Tissue Biochemical Markers
Folate
(ng/ml)
Total-C
(mg/dl)
HDL-C
(mg/dl)
Homocysteine
(mol/l)
Plasma NOx
(nmol/ml)
Tissue NOx
(nmol/g tissue)
Tissue cGMP
(fmol/g tissue)
Control 44  4 47  3 20  2 4.6  1 14  1 35  3 44  1
HC 37  4 64  7* 17  1* 7  1† 9.1  1* 27  1* 38  2*
HCF 132  16† 56  4* 16  1* 4  1*§ 15  3‡ 49  5*§ 56  3*§
HCFL-NAME 206  11† 59  5* 19  1 n.m. 5.7  1 n.m. n.m.
*p  0.05; †p  0.001 vs. control; ‡p  0.05; §p  0.01 vs. HC; p  0.01 vs. HCF.
C  cholesterol; cGMP  cyclic guanosine monophosphate; HDL  high-density lipoprotein; n.m.  not measured; NOx  nitratenitrite. Other abbreviations as in Table 1.
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Figure 1. (A) Representative laser Doppler blood flow (LDBF) images at days 7, 14, and 28 are shown. (B) Before and after surgery, the hindlimb LDBF ratio did not differ among the three groups. The
control group revealed progressive recovery of the ischemic/normal LDBF ratio within 28 days after induction of limb ischemia. However, the LDBF ratio was lower in the hypercholesterolemia (HC) group
than in the controls. In the HC  Folate group, the LDBF ratios were significantly improved compared with the HC group; n  6 in each group. *p  0.05; **p  0.01 vs. control; †p  0.05; ††p  0.01
vs. HC.
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Figure 2. (A) Representative postmortem angiograms taken at day 14 are shown. There are numerous collateral vessels in the medial thigh area in the
control group. However, the hypercholesterolemia (HC) group showed reduced collateral vessels. Folate supplementation (HC  Folate group) increased
collateral vessels. (B) The angiographic score was significantly lower in the HC than in the control group, which was rescued in the HC  Folate group.
n  6 in each group; ***p  0.001.
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proliferation (27). Taken together, endothelial dysfunction
with decreased EDNO formation and increased superoxide
releases are probably responsible for the impaired angiogen-
esis in the HC state.
Folate restored ischemia-induced angiogenesis in
HC. Recent studies indicate that a low level of plasma
folate is associated with the increased risk of cardiovascular
disease (28). Conversely, folate supplementation preserved
endothelial function in patients with cardiovascular risk
factors (7–11). The present study is the first to show that
oral folate administration has favorable impacts on
ischemia-induced angiogenesis. Folate supplementation
augmented both angiographically visible (diameter 200
m) collateral vessel formation (i.e., arteriogenesis) and
histologic capillary vessel formation (i.e., angiogenesis) (29).
There may be several possible mechanisms for the beneficial
actions of folate on arteriogenesis/angiogenesis. First, folate
may have restored endothelial function via a regeneration of
BH4 because folate and its active metabolite metabolite
5-methyltetrahydrofolate are involved in the synthesis of
BH4 that is an essential cofactor for eNOS (7–9). In fact,
the ability of eNOS to produce superoxide anion depends
on the deficiency of BH4 (21). Thus, regeneration of BH4
by folate supplementation may have resulted in the reduced
amount of superoxide anion and enhanced NO formation.
This hypothesis is further supported by the present findings
that HC suppressed tissue NOx and cGMP contents,
whereas folate supplementation restored the levels of these
molecules.
In the present study, treatment with L-NAME com-
pletely blocked the beneficial effects of folate on angiogen-
esis in the HC state. Both ischemic/normal LDBF ratio and
angiographic score (arteriogenesis) were suppressed by
L-NAME down to levels even lower than those observed in
the HC group. These indicate that not only angiogenesis
but also arteriogenesis depends on basal EDNO bioactivity.
Consistently, Matsunaga et al. (30) reported that arterio-
genesis in the ischemic tissues depends on vascular endo-
thelial growth factor-mediated endothelial NO release. We
also previously reported that arteriogenesis was suppressed
by hypercholesterolemia, which was rescued by L-arginine,
a precursor of NO (6). Lloyd et al. (31) reported using a rat
model of limb ischemia that, again, arteriogenesis depends
Figure 3. (A) The capillary density was significantly lower in the hypercholesterolemia (HC) group than in the control group in the ischemic hindlimb,
which was restored in the HC  Folate group. In the nonischemic hindlimb, the capillary densities did not differ among the three groups. (B) Similarly,
the capillary/muscle fiber ratio was significantly lower in the HC group than in the control group in the ischemic hindlimb, which was restored in the HC
 Folate group. In the nonischemic hindlimb, the capillary/muscle fiber ratio did not differ among the three groups. n  6 in each group; ***p  0.001.
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on NO. These studies collectively support that EDNO is an
important factor for angiographically visible arteriogenesis.
Second, folate may have restored endothelial function via
a homocysteine-dependent pathway. Studies showed that
HC was associated with hyperhomocysteinemia (32), an
atherothrombotic risk factor that inhibits endothelial func-
tion (33,34). Folate is involved in the metabolic pathway of
homocysteine, and folate supplementation has been shown
to reduce plasma homocysteine levels (13). A recent study
indeed showed that folate supplementation ameliorated
hyperhomocysteinemia-related renal ischemia (35). The
present study showed that plasma homocysteine concentra-
tions were increased in the HC group compared with the
control group, while oral folate supplementation reduced
plasma homocysteine concentrations to levels similar to
those of the control group (Table 2). Thus, it is likely that
folate reversed homocysteine-induced endothelial dysfunc-
tion, which may be an additional mechanism for the
folate-mediated restoration of ischemia-induced angiogen-
esis in the HC state (36). Finally, folate supplementation
did not affect serum total cholesterol or HDL-cholesterol
levels. Therefore, the restoration of angiogenesis by oral
folate is not likely to be mediated by alteration of serum
lipid profiles.
Study limitations. In the present study, the LDBF ratio in
the HC rats kept up with that of control rats in chronic
phase. In this sense, our rat model of limb ischemia may not
mimic patients with chronic peripheral-artery occlusive
disease. One may consider that HC might have simply
slowed the recovery of the LDBF ratio and folate acceler-
ated the recovery process. Nevertheless, supplemental folate
significantly improved angiogenesis at days 7 through 28
after ischemia, which is a critical time period for endothelial
regeneration. Second, we administered 5 mg/kg/day of
folate to each animal. This dose is almost identical to 250
mg/day in humans and is apparently high. Therefore, it is
still unknown whether clinical doses of folate have similar
efficacies in humans. Third, serum cholesterol levels in HC
rats were relatively low compared with other studies. The
reason is unknown, but our method of cholesterol measure-
ments revealed a significant and definite difference between
the control and HC groups. Therefore, high cholesterol diet
at least induced an HC state in our rat model. Finally,
although folate increased the number of capillaries in the
ischemic tissues, the role of direct vasodilating action of
folate on angiogenesis or arteriogenesis should be taken into
account because folate can directly augment endothelium-
dependent vasodilation.
Conclusions. Supplemental oral folate restored the im-
paired ischemia-induced angiogenesis in the HC state. The
mechanism is likely to be related to the folate-mediated
restoration of endothelial function and endogenous NO
formation. Oral folate administration may be a feasible
therapeutic means to increase angiogenesis and collateral
vessel formation in patients with peripheral-artery occlusive
disease complicated with dyslipidemia.
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Figure 4. The effects of nitric oxide inhibition on angiogenesis. (A) Before and after surgery, the ischemic/normal laser Doppler blood flow (LDBF) ratio
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score was greater in the HC  Folate group than in the HC group. The score was significantly suppressed by L-NAME treatment (HC  Folate 
L-NAME group). n  6 in each group **p  0.01; ***p  0.001.
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